Richter's New Drug to Take Years to Offset Russia Woes, CEO Says

Updated on
  • Richter to book milestone payment in the third quarter
  • Cariprazine will be game-changer for Richter, CEO Bogsch says

Gedeon Richter Nyrt. is counting on the drug developed jointly with Allergan Plc to offset declines in its Russian and Ukrainian markets, once sales of the new antipsychotic take off worldwide from 2018, Chief Executive Officer Erik Bogsch said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.